Literature DB >> 27064856

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.

Amar Mannina1, Jonathan H Chung2, Jeffrey J Swigris1, Joshua J Solomon1, Tristan J Huie1, Zulma X Yunt1, Tho Q Truong3, Kevin K Brown1, Rosane Duarte Achcar4, Amy L Olson1, Christian W Cox5, Seth J Kligerman6, Douglas Curran-Everett7, Evans R Fernández Pérez1.   

Abstract

RATIONALE: Granulomatous-lymphocytic interstitial lung disease (GLILD) has emerged as a major cause of morbidity in patients with common variable immunodeficiency (CVID). While GLILD is among the most serious noninfectious pulmonary complications of CVID, risk factors for this condition have not been reported.
OBJECTIVES: To identify clinical, physiologic, and serologic risk factors for GLILD in adults with CVID.
METHODS: Of 345 consecutive adult patients with CVID, we identified 34 in the National Jewish Health research database who had a radiographic-pathologic diagnosis of GLILD evaluated between 2002 and 2014. Each case was age and sex matched to 52 CVID control subjects. We used logistic regression to determine independent predictors of GLILD. A mixed effects model was used to estimate the longitudinal change in percent predicted FVC.
MEASUREMENTS AND MAIN RESULTS: The mean time from CVID diagnosis to GLILD detection was 7.8 years. Compared with matched control subjects, cases were more likely to have a history of autoimmune cytopenia, hypersplenism, polyarthritis, lower marginal zone and switched memory B cells, and restrictive lung function. Multivariate analysis revealed that hypersplenism (odds ratio [OR], 24; 95% confidence interval [CI], 4.5-179.1), polyarthritis (OR, 19; 95% CI, 2.3-206.8), and percent predicted FVC (OR, 0.93; 95% CI, 0.87-0.98) were independently associated with the development of GLILD. The rate of change of percent predicted FVC (slope, P = 0.48) did not vary significantly in patients with GLILD over a mean follow-up of 7 years after diagnosis.
CONCLUSIONS: Hypersplenism and polyarthritis are strong risk factors for GLILD in patients with CVID. Percent predicted FVC remained stable over time in patients with GLILD.

Entities:  

Keywords:  common variable immunodeficiency; cytopenia; granulomatous lymphocytic interstitial lung disease; polyarthritis; splenomegaly

Mesh:

Year:  2016        PMID: 27064856     DOI: 10.1513/AnnalsATS.201511-728OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  14 in total

1.  Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry.

Authors:  Elizabeth J Feuille; Niloofar Anooshiravani; Kathleen E Sullivan; Ramsay L Fuleihan; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2017-10-28       Impact factor: 8.317

Review 2.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

3.  FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).

Authors:  S Jolles; E Carne; M Brouns; T El-Shanawany; P Williams; C Marshall; P Fielding
Journal:  Clin Exp Immunol       Date:  2016-11-28       Impact factor: 4.330

4.  Interstitial Lung Disease Frequently Precedes CVID Diagnosis.

Authors:  Leif G Hanitsch; Kirsten Wittke; Anna Barbara Stittrich; Hans Dieter Volk; Carmen Scheibenbogen
Journal:  J Clin Immunol       Date:  2019-10-22       Impact factor: 8.317

Review 5.  Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review.

Authors:  Amika K Sood; William Funkhouser; Brian Handly; Brent Weston; Eveline Y Wu
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

Review 6.  The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation.

Authors:  Ulrich Baumann; John M Routes; Pere Soler-Palacín; Stephen Jolles
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

7.  Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype.

Authors:  Riccardo Scarpa; Federica Pulvirenti; Antonio Pecoraro; Alessandra Vultaggio; Carolina Marasco; Roberto Ria; Sara Altinier; Nicolò Compagno; Davide Firinu; Mario Plebani; Marco De Carli; Andrea Matucci; Fabrizio Vianello; Angelo Vacca; Giuseppe Spadaro; Isabella Quinti; Carlo Agostini; Cinzia Milito; Francesco Cinetto
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

8.  Analysis of Granulomatous Lymphocytic Interstitial Lung Disease Using Two Scoring Systems for Computed Tomography Scans-A Retrospective Cohort Study.

Authors:  Jennifer J Meerburg; Ieneke J C Hartmann; Sigune Goldacker; Ulrich Baumann; Annette Uhlmann; Eleni-Rosalina Andrinopoulou; Mariette P C Kemner V/D Corput; Klaus Warnatz; Harm A W M Tiddens
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

9.  Interstitial Lung Disease in Children With Selected Primary Immunodeficiency Disorders-A Multicenter Observational Study.

Authors:  Małgorzata Pac; Teresa Bielecka; Katarzyna Grzela; Justyna Komarnicka; Renata Langfort; Sylwia Koltan; Nel Dabrowska-Leonik; Katarzyna Bernat-Sitarz; Maciej Pronicki; Hanna Dmenska; Anna Pituch-Noworolska; Bozena Mikoluc; Barbara Piatosa; Katarzyna Tkaczyk; Ewa Bernatowska; Irena Wojsyk-Banaszak; Katarzyna Krenke
Journal:  Front Immunol       Date:  2020-08-27       Impact factor: 7.561

10.  Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease.

Authors:  David Friedmann; Susanne Unger; Baerbel Keller; Mirzokhid Rakhmanov; Sigune Goldacker; Gernot Zissel; Björn C Frye; Jonas C Schupp; Antje Prasse; Klaus Warnatz
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.